Pro-ocular™

Case Studies

128

Patients Over Two Years

Completed Phase 2 Studies

Peer Reviewed Publications

Pro-ocular® for Contact Lens Dry Eye

Baseline

Dose + 6 min.

Dose + 2 hours

Baseline:

Lens sticking to eye and little tear film in front or behind contact lens

Same Eye, Dose + 15 min.:

New tear film enables lens to float – eliminating dry eye and increasing contact lens wear time

Pro-ocular® for oGvHD Severe Dry Eye

Before Pro-Ocular

Functionally blind – seeing 20/250 with “inoperable” cataracts due to fragile corneas

2 Weeks on Pro-ocular

Getting relief in symptoms, still functionally blind

1 Year on Pro-ocular

Months 10 &11 bi-lateral cataract surgery while on Pro-ocular with vision correct to 20/20

Subject reported 6 years later seeing 20/20 in both eyes while using Pro-ocular

Join Our Mission

Signal12 is raising capital to complete Phase 3 trials and bring Pro-ocular to market. Invest in a future where dry eye sufferers can enjoy lasting relief and improved vision.

Pro-ocular™
Clinical Trials
Company
Leadership

Signal12 Inc.

Signal12 is a clinical-stage dry eye company that develops novel therapies to address ophthalmic diseases. Through three Phase 2 clinical studies, the company’s proprietary topical drug, Pro-ocular™ has demonstrated efficacy in safely and effectively reducing the signs and symptoms of dry eye disease (DED). Pro-ocular™ is the first product for DED to utilize transappendageal delivery, and the only product to treat DED by targeting the ophthalmic branch of the trigeminal nerve. The company has offices in Greenwich, CT and Boston, MA.

Signal12 is actively raising capital to complete Phase 3 clinical trials and bring Pro-ocular™ to market. For information on investment opportunities, please email Neil Edwards at [email protected].